Dr Provencio and his team, who specialise in lung cancer, have extensive experience in the field of medical oncology. Their work, whilst always patient-centred, includes not only clinical research but also translational research, featuring a Liquid Biopsy Laboratory that specialises in the analysis of circulating tumour DNA, focused on monitoring the disease using minimally invasive methodology.

Over the past 5 years, the IDIPHIM Translational Lung Cancer Research Group (GITCP-IDIPHIM) has been awarded various national and international R&D&I projects (H2020, PIE, FIS) totalling over 2 million euros. Furthermore, the lung group secured funding under the 2014 AES framework with the achievement of an ISCiii Integrated Project of Excellence (PIE14/00064), which recently concluded, thereby establishing the background for the current scientific programme: personalised medicine, liquid biopsy and mass data analysis.

Thanks to the results and experience gained within the framework of project PIE14/00064, the GITCP-IDIPHIM has secured two European H2020 projects (2016 and 2017) in international multidisciplinary consortia: “IASIS - Integration and analysis of heterogeneous big data for precision medicine and suggested treatments for different types of patients” and “BigMedilytics: Big Data for Medical Analytics”. The unifying theme in both projects is the application of big data techniques, clinical data and liquid biopsy to improve the management and survival of lung cancer patients, as well as national health systems.